Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
Date:7/28/2009

as compared to $3.8 million during the corresponding period of Fiscal 2009, representing a decrease of 4%. SG&A expenses, as a percentage of net sales increased to 8% for the first three months of Fiscal 2010, as compared to 4% for the corresponding period of Fiscal 2009. The higher percentage of SG&A is primarily due to the lower sales in the current period versus the corresponding period last year.

Total R&D expenses for the first quarter of Fiscal 2010 were $7.1 million, as compared to $5.5 million during the corresponding period of Fiscal 2009. The R&D expenses during the first quarter of Fiscal 2010 were higher compared to those during the corresponding period of Fiscal 2009 as we incurred increased expenses relating to bio-equivalency studies for certain products under development and increased patent related expenses in an effort to expand our product portfolio. We did not file any Abbreviated New Drug Applications ("ANDAs") with the FDA during the first quarter of Fiscal 2010. We have not received FDA approval for any ANDAs during the first quarter of Fiscal 2010 and do not expect to receive any approvals until we resolve the FDA's concerns. The total number of ANDAs pending approval by the FDA as of June 30, 2009 was 29 (including four tentative approvals) relating to 25 products.

We incurred a net pre-tax loss of $14.4 million during the first quarter of Fiscal 2010, as compared to net pre-tax income of $14.6 million during the corresponding period of Fiscal 2009. Net pre-tax income was lower because of the $8.4 million inventory reserve, as disclosed above, and the decreased sales. During the first quarter of Fiscal 2010, we provided for an income tax benefit of $5.0 million, as compared to an income tax expense of $5.1 million in the corresponding period of Fiscal 2009. We incurred a net loss of $9.4 million during the first quarter of Fiscal 2010, as compared to net income of $9.4 million d
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (HealthDay News) -- Drugs commonly used to treat glaucoma ... can interfere with vision, according to a new study. ... are used to reduce eye pressure, have already been ... eye color, the researchers said, suggesting that the new ... Doctors should be conservative when prescribing these drugs, ...
(Date:5/24/2013)... researchers failed to replicate what appeared to be breakthrough ... they were published last year in the journal ... 2012, suggested that the drug bexarotene (marketed as Targretin) ... (Aβ) a pathological hallmark of Alzheimer,s disease ... of the 2012 report, drug treatment quickly removed most ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... da Vinci lawsuit involving Intuitive Surgical Inc.’s da ... According to court records, a Washington State Court ... not committed negligence in training a surgeon who performed ... several years later. The patient’s family had alleged ...
(Date:5/24/2013)... 24, 2013 Dwell Media LLC ... Huff as Executive Vice President of Digital for Dwell ... which represented a large portion of Yahoo's global media ... Dwell develops a fully-integrated commerce unit to launch in ... monetizing digital content for leading firms in Silicon Valley. ...
(Date:5/24/2013)... 24 (HealthDay News) -- People with high levels of ... die of liver disease than those with lower levels, ... cadmium in urine is evidence of long-term exposure to ... and tobacco smoke, the Johns Hopkins researchers explained. ... cadmium directly causes liver disease but instead suggest an ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Increased roadway pollution produced by diesel fuel in vehicles ... result in heart attack or stroke, researchers suggested in ... American Heart Associations Scientific Sessions 2007., United Kingdom and ... and blood platelet activity in healthy volunteers which ...
... danger, study suggests , , TUESDAY, Nov. 6 (HealthDay News) ... and could pose risks to people with hypertension and ... found that drinking two cans of a popular energy ... healthy adults, average age 26. , Within a few ...
... of antioxidants, vitamins and electrolytes offer healthiest ... benefits in new functional water, PLANO, ... a one-two punch, Snapple,s introduction of Antioxidant Water and,LYTeWater takes drinking ... offers a smart solution that,improves energy, helps restore the body and ...
... Nov. 6 Neurotech Pharmaceuticals, Inc.,a biotechnology ... for chronic retinal diseases, announced today the ... Each study is evaluating,NT-501, the Company,s lead ... with retinitis pigmentosa (RP) and the dry ...
... SEATTLE, Nov. 6 On Thursday, November 8,2007, at ... Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC and ... to discuss the,company,s 2007 third quarter achievements and financial ... November 8 8:30 a.m. Eastern/2:30 p.m. Central ...
... CALL AND WEBCAST TO FOLLOW, BIRMINGHAM, Ala., Nov. ... announced that its third quarter,2007 financial results will be ... Time, BioCryst will host a conference call and live,webcast. ... President and Chief,Executive Officer, and Stuart Grant, Senior Vice ...
Cached Medicine News:Health News:Diesel exhaust associated with higher heart attack, stroke risk in men 2Health News:Diesel exhaust associated with higher heart attack, stroke risk in men 3Health News:Energy Drinks Could Pose Blood Pressure Risks 2Health News:Snapple's New Antioxidant Water and LYTeWater Take Hydration to the Next Level 2Health News:Snapple's New Antioxidant Water and LYTeWater Take Hydration to the Next Level 3Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 2Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 3Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 4
(Date:5/23/2013)... , May 23, 2013 Anthem Blue ... that would have required them to obtain their medications ... Consumer Watchdog and Whatley Kallas LLC.  ... Court, alleged that Blue Cross,s mandatory mail order program ... their health and privacy. "This settlement brings ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... , May 23, 2013  Ameritox, the ... selected by Progressive Medical, Inc. to become part ... help clients manage pharmacy costs and improve the ... Medical, a leading pharmacy benefit manager in the ... overall medication compliance and pain management strategy for ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... 2011 GlaxoSmithKline (GSK) is committed to ensuring that ... and alli. alli is safe and effective when used ... and works locally in the gastro-intestinal tract. GSK continues ... share all relevant information with regulatory agencies. ...
... April 14, 2011 Freedom Innovations, a company ... lower extremity prosthetic devices, today announced a worldwide ... rights to commercialize the world,s first lower extremity ... that operate synergistically.  Developed at the Vanderbilt University ...
Cached Medicine Technology:Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
Medicine Products: